Shearman & Sterling advised HalioDx and its shareholders on the contemplated sale of HalioDx, an immuno-oncology diagnostics company pioneering the immunological diagnosis of cancers, to Veracyte, Inc., a U.S. company listed on the NASDAQ specialized in high-value advanced genomic tests, for a purchase price of €260 million.

HalioDx is an immuno-oncology diagnostic company providing oncologists and drug development organizations with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Leveraging the pioneering work of Dr. Jérôme Galon, who received the European Inventor Award in 2019, HalioDx provides a unique range of immune scoring solutions, including its flagship Immunoscore® assay for assessing the immune contexture of a tumor as a key determinant of patients’ outcomes and response to cancer treatments.

Shearman & Sterling also advised HalioDx in connection with its Series B investment for €18.2 million in 2018 and during the spin-off with Qiagen in 2015.

The Team